Exchange: NASDAQ·Updated 04:13 PM EDT
BMRN logo

BMRNBiomarin Pharmaceutical Inc. - Registered Shares

$56.50
$0.60
(1.07%)
Today
Closed $56.50
$0.00
(0.00%)
After Hours
EarningsAug 3
Mkt Cap$10.8B
Vol1.98M
News
all
press releases
BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 PR Newswire SAN RAFAEL, Calif., June 16, 2026 Data from an...
PR Newswire
News Placeholder
More News
News Placeholder
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years...
Yahoo! Finance: News
News Placeholder
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development...
Yahoo! Finance: News
News Placeholder
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
BMRN's shares rise after Voxzogo hits the main goal in a late-stage hypochondroplasia study, supporting planned FDA filings in 2026.
Zacks
News Placeholder
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia PR Newswire SAN RAFAEL, Calif., May 20, 2026 Study met primary...
PR Newswire
News Placeholder
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
Zacks
News Placeholder
BioMarin Pharmaceutical Enters Oversold Territory (BMRN)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
News Placeholder
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency PR...
PR Newswire
News Placeholder
Here Are Monday's Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy's, and More
Here Are Monday's Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy's, and More...
Yahoo! Finance: News
<
1
2
...
>

Advertisement|Remove ads.